Drug Discovery Articles

Elabscience Promotion: Recombinant antibodies buy two get the 3rd free

ELABSCIENCE PROMOTIONBuy 2 Get 1 Free: Elabscience Recombinant Rabbit Monoclonal AntibodiesLAB-A-PORTER is the authorized distributor of Elabscience in Hong Kong, providing academic and biotech research institutions with sourcing, official HKD quotations, and...

Bio X Cell Promotion – Starting a new Mouse model project? Get your first 1mg in vivo antibody for FREE*!

BIO X CELL PROMOTIONFree Bio X Cell In Vivo Antibody Promotion for Mouse Model ResearchResearchers starting new mouse model projects can receive a complimentary 1mg vial of Bio X Cell InvivoMab antibody or 50% off a 5mg vial through LAB-A-PORTER. This limited-time...

IL-23: A Key Target for the Treatment of Immune-Mediated Inflammatory Diseases

ARTICLE FROM KACTUS IL-23: A Key Target for the Treatment of Immune-Mediated Inflammatory Diseases In KACTUS ’s recent feature, Lauren He from KACTUS introduced a comprehensive overview of Interleukin-23 (IL-23) and its role in driving immune-mediated inflammatory...

Translational Continuity: Why Drug Programs Fail Early

ARTICLE BY BIO X CELLTranslational Continuity: Why Drug Programs Fail EarlyIn a recent blog post titled "Translational Continuity: Why Drug Programs Fail Early," Bio X Cell introduced insights into why over 90% of drug candidates fail during clinical trials. A...

Hematopoietic growth factors and cytokines from Qkine

Apr 8, 2026 | Drug Discovery, Immunology, Research Area, Stem Cell

Hematopoietic growth factors and cytokinesHematopoiesis is the process where hematopoietic stem cells (HSCs) undergo...

CDCP1: A New Therapeutic Target for Malignant Tumors – Article from KACTUS

Apr 1, 2026 | Cancer, Drug Discovery, Immunology, Stem Cell

RESOURCES FROM KACTUS Article: CDCP1: A New Therapeutic Target for Malignant Tumors Natasha Slepak from KACTUS...

Article by Bio X Cell: Translational Continuity: Why Drug Programs Fail Early

Apr 1, 2026 | Drug Discovery, Immunology, in vivo Studies, Organoids, Stem Cell

ARTICLE BY BIO X CELLTranslational Continuity: Why Drug Programs Fail EarlyBio X Cell has recently published an...

Introducing Peprotech Human FGF-7 (KGF) Recombinant Protein (Catalog #100-19)

Jul 4, 2025 | Cancer, Disease Modelling, Drug Discovery, Organoids, Promotion, Stem Cell

Human FGF-7 (KGF) Recombinant Protein (Catalog #100-19)Product Specifications Recombinant Human KGF (FGF-7) is an 18.9...

Introducing Peprotech Human FGF-10 Recombinant Protein (Catalog #100-26)

Jul 4, 2025 | Cancer, Disease Modelling, Drug Discovery, Organoids, Promotion, Stem Cell

Introducing Peprotech Human FGF-10 Recombinant Protein (Catalog #100-26)Product Specifications Recombinant Human...

Article from Bio X Cell: How to Choose an Anti-CTLA-4 Antibody for Your Research

Jul 1, 2025 | Cancer, Disease Modelling, Drug Discovery, Immunology, Immunotherapy, in vivo Studies

ARTICLE FROM BIO X CELLHow to Choose an Anti-CTLA-4 Antibody for Your ResearchBio X Cell has published an article...

Article from KACTUS: Immunotherapy Target: CD19 Antigen

Jul 1, 2025 | Cancer, CGT Research, Drug Discovery, Immunology, Stem Cell

RESOURCES FROM KACTUS Article: Immunotherapy Target: CD19 Antigen In this article, KACTUS discussed the Cluster of...

Post #ISSCR2025 product highlight series – Bio X Cell in vivo antibodies

Jun 24, 2025 | Drug Discovery, Immunology, in vivo Studies

Post #ISSCR2025 product highlight series by LAB-A-PORTER Bio X Cell: In-vivo antibodies used for drug discovery...

Post #ISSCR2025 product highlight series – GeneTex stem cell markers

Jun 24, 2025 | Drug Discovery, Stem Cell

Post #ISSCR2025 product highlight series by LAB-A-PORTER GeneTex: Antibodies against cell markers for detection in...

Why In Vivo-Formulated Antibodies Excel in Ex Vivo Systems

May 28, 2025 | Cancer, Disease Modelling, Drug Discovery, Immunology, in vivo Studies

ARTICLE FROM BIO X CELLWhy In Vivo Formulation Antibodies Are a Natural FitTechnologies such as artificial...

Download brochure: Recombinant Antibodies for GPCRs from GeneTex

May 7, 2025 | Cancer, Drug Discovery, Immunology

PRODUCT HIGHLIGHTS GENETEX: RECOMBINANT ANTIBODIES FOR GPCRS (G PROTEIN-COUPLED RECEPTORS)G protein-coupled receptors...

Bio X Cell published a publication highlight: Bio X Cell BE0101 in Action: IL-16 Remodels the Tumor Immune Microenvironment and Boosts Immunotherapy Efficacy

Apr 30, 2025 | Cancer, Disease Modelling, Drug Discovery, Immunology, in vivo Studies

ARTICLE FROM BIO X CELLPublication Spotlight | Bio X Cell BE0101 in Action: IL-16 Remodels the Tumor Immune...